Abstract
To study the long-term safety and effectiveness of ipratropium bromide nasal spray 0.03% in the treatment of nonallergic perennial rhinitis, we administered this medication for 1 year in an open-label trial involving 285 patients. Our intention was to maintain the highest protocol dose possible to gain a clearer picture of the long-term side effect profile of the compound. Ipratropium bromide was well tolerated with no serious side effects in this patient population. It provided a significant improvement in rhinorrhea throughout the year-long trial; only 17 of 285 patients (6%) were considered treatment failures. There was an improvement in patient quality of life, as well as a substantial reduction in the need for other medications (antihistamines, decongestants, and nasal steroids) used to treat perennial rhinitis symptoms. (J ALLERGY CLIN IMMUNOL 1995;95:1123-7.).
Original language | English (US) |
---|---|
Pages (from-to) | 1123-1127 |
Number of pages | 5 |
Journal | The Journal of allergy and clinical immunology |
Volume | 95 |
Issue number | 5 SUPPL. |
DOIs | |
State | Published - May 1995 |
Externally published | Yes |
Keywords
- Nonallergic rhinitis
- chronic
- efficacy
- ipratropium
- nasal spray
- safety
ASJC Scopus subject areas
- Immunology and Allergy
- Immunology